human
norovirus
major
caus
agent
sporad
epidem
gastroenter
children
adult
current
licens
therapeut
intervent
measur
either
term
vaccin
drug
avail
highli
contagi
human
pathogen
genet
antigen
divers
virus
rapid
emerg
new
strain
abil
infect
broad
popul
use
polymorph
histoblood
group
antigen
cell
attach
pose
signific
challeng
develop
effect
antivir
agent
despit
impedi
progress
design
develop
therapeut
agent
includ
capsidbas
candid
vaccin
potenti
antivir
either
form
glycomimet
design
antibodi
block
hbga
bind
well
target
essenti
nonstructur
protein
viral
proteas
rnadepend
rna
polymeras
addit
classic
approach
recent
studi
suggest
possibl
interferon
target
host
cell
factor
viabl
approach
counter
noroviru
infect
review
provid
brief
overview
progress
human
norovirus
hunov
common
caus
epidem
sporad
case
acut
gastroenter
worldwid
us
alon
hunov
caus
approxim
million
case
acut
gastroenter
annual
age
group
hunov
infect
lifethreaten
especi
elderli
immunocompromis
transplant
patient
high
risk
seriou
prolong
chronic
ill
recent
year
success
rotaviru
vaccin
young
children
hunov
replac
rotavirus
common
caus
gastroenter
age
group
econom
burden
hunov
infect
us
estim
billion
develop
countri
hunov
estim
caus
million
hospit
death
children
year
age
occur
annual
hunov
belong
genu
noroviru
one
five
major
genera
calicivirida
famili
icosahedr
virus
positivesens
singlestrand
rna
genom
exhibit
enorm
genet
divers
phylogenet
divid
least
six
genogroup
gigvi
gi
gii
giv
genogroup
contain
human
pathogen
genogroup
divid
sever
genotyp
hunov
belong
genogroup
ii
genotyp
preval
account
major
global
outbreak
epidemiolog
studi
suggest
strain
undergo
epoch
evolut
new
variant
emerg
everi
year
recent
studi
also
show
outbreak
involv
gi
strain
becom
increasingli
preval
worldwid
certain
gi
genotyp
predomin
differ
geograph
region
preponder
global
hunov
outbreak
period
emerg
new
variant
pose
major
health
concern
current
effect
vaccin
antivir
avail
counter
hunov
infect
genet
antigen
divers
hunov
lack
naturallyoccur
longstand
immun
possibl
signific
challeng
develop
effect
vaccin
offer
widespread
crossprotect
howev
signific
effort
led
develop
bival
vaccin
base
genotyp
gi
present
vaccin
construct
encod
wherea
encod
polyprotein
process
virallyencod
proteas
nonstructur
protein
nsp
exhibit
modular
domain
organ
consist
domain
form
ntermin
residu
provid
scaffold
protrud
p
domain
subdivid
subdomain
fig
distal
locat
surfaceexpos
subdomain
consid
larg
insert
subdomain
harbor
sequenc
variat
across
genogroup
genotyp
respons
mani
virushost
interact
recombin
vlp
morpholog
antigen
similar
authent
hunov
capsid
highli
immunogen
vlp
made
hunov
genotyp
suggest
possibl
design
multival
vaccin
select
multipl
genotyp
addit
vlp
recombin
p
domain
elicit
strong
immun
respons
suggest
possibl
candid
vaccin
develop
effort
even
effect
vaccin
becom
avail
great
interest
develop
antivir
drug
antivir
treatment
could
use
therapi
chronic
infect
immunocompromis
patient
treatment
prophylaxi
outbreak
situat
ongo
transmiss
continu
occur
nurs
home
outbreak
prophylaxi
certain
circumst
travel
medic
safe
vaccin
unavail
treatment
acut
ill
particularli
young
old
hospit
patient
symptom
may
last
week
target
design
develop
antihunov
drug
suscept
hunov
infect
associ
express
histoblood
group
antigen
hbga
found
mucos
secret
epitheli
cell
geneticallydetermin
glycoconjug
function
initi
cell
attach
factor
hunov
uniqu
requir
bind
polymorph
hbga
may
influenc
evolut
nov
strain
hunov
bind
hbga
hypervari
subdomain
protrud
p
domain
studi
use
vlp
p
domain
construct
shown
hunov
result
variat
subdomain
exhibit
strainspecif
hbga
bind
pattern
crystallograph
studi
p
domainhbga
complex
show
hbga
bind
site
distinct
gi
gii
sequenc
chang
around
conserv
hbga
site
within
genogroup
allow
modul
hbga
bind
profil
fig
fig
sequenc
chang
result
signific
alter
structur
electrostat
topographi
subdomain
consist
straindepend
antigen
variat
observ
chang
close
proxim
hbga
bind
site
consist
notion
coordin
interplay
variat
hbga
bind
profil
antigen
critic
factor
drive
evolut
hunov
although
differ
hbga
bind
profil
genotyp
within
genogroup
also
conserv
featur
exampl
genotyp
gi
gii
genogroup
primarili
recogn
galactos
fucos
residu
hbga
respect
structur
element
includ
amino
acid
residu
respect
subdomain
genogroup
coordin
bind
galactos
fucos
moieti
highli
conserv
case
gii
p
domain
crystallograph
studi
shown
fucos
alon
bind
set
subdomain
residu
termin
fucos
residu
hbga
interestingli
citrat
togeth
water
molecul
mimick
pyranosid
ring
fucos
also
bind
effect
site
furthermor
recent
studi
shown
oligosaccharid
deriv
human
milk
bind
site
gii
hbga
block
hbga
bind
observ
rais
possibl
hbga
bind
site
potenti
target
design
glycomimet
small
molecul
inhibit
hbga
bind
howev
interact
hbga
gener
occur
low
affin
low
micromolar
rang
design
potent
glycomimet
may
challeng
task
feasibl
approach
may
design
antivir
base
monoclon
antibodi
mab
inhibit
hunovhbga
interact
particularli
consid
recent
studi
identifi
antibodi
sera
hunov
infect
patient
design
develop
suitabl
mab
deriv
singlechain
antibodi
fragment
also
call
vhh
nanobodi
disulphidestabil
singlechain
antibodi
fragment
particularli
target
entri
mechan
consider
prophylact
therapeut
use
counter
virus
influenza
viru
rabi
viru
ebola
viru
hepat
b
viru
adapt
humor
immun
also
involv
resist
hunov
infect
serum
antibodi
block
interact
viru
hbga
associ
lower
risk
develop
infect
ill
follow
exposur
viru
antibodi
propos
function
similar
hemagglutin
inhibit
neutral
antibodi
influenza
viru
hbgablock
antibodi
vari
specif
genotypespecif
variantspecif
even
strainspecif
among
global
preval
nov
emphas
correl
interplay
antigen
hbga
specif
evolut
nov
human
monoclon
antibodi
block
hbga
bind
isol
produc
peripher
blood
mononuclear
cell
blood
donor
character
date
appear
genotypespecif
addit
nanobodi
block
hbga
bind
gii
vlp
identifi
character
current
mechan
antibodi
block
hbga
bind
unclear
structur
studi
p
domain
complex
fab
mab
nanobodi
provid
mechanist
detail
blockad
activ
leverag
design
antibodyscaffold
antibodylik
molecul
hunovspecif
therapeut
agent
note
earlier
hunov
encod
polyprotein
proteolyt
process
virusencod
proteas
least
six
nsp
nsp
nto
cterminu
polyprotein
includ
whose
precis
function
yet
determin
ntpase
distinct
highli
conserv
helicas
motif
similar
picornaviru
share
sequenc
similar
picornaviru
possibl
function
antagonist
golgidepend
cellular
protein
secret
vpg
coval
link
viral
rna
proteas
similar
picornaviru
rnadependentrna
polymeras
rdrp
ortholog
picornaviru
pol
six
nsp
proteas
rdrp
consid
potenti
antivir
target
structur
function
well
character
also
picornaviru
homologu
studi
extens
develop
antivir
proteolyt
process
polyprotein
virallyencod
proteas
common
essenti
step
replic
rna
virus
includ
hunov
unlik
cellular
proteas
gener
target
one
site
viral
proteas
recogn
cleav
multipl
specif
site
polyprotein
critic
function
viral
replic
viral
proteas
includ
hunov
proteas
attract
target
design
develop
small
molecul
drug
inhibit
proteolyt
process
typic
proteas
inhibitor
short
peptid
mimic
ntermin
residu
preced
cleavag
site
substrat
polyprotein
modifi
posit
attach
adduct
aldehyd
keton
ester
bisulfit
electrophil
warhead
inhibitor
bind
activ
site
irrevers
coval
modifi
activesit
nucleophil
residu
inhibit
proteolyt
activ
hunov
proteas
similar
picornaviru
cystein
proteas
chymotrypsinlik
fold
compris
two
domain
separ
cleft
activ
site
locat
activ
site
consist
catalyt
triad
cystein
nucleophil
histidin
gener
base
catalyst
glutam
acid
anion
orient
imidazol
ring
histidin
crystal
structur
hunov
proteas
complex
substrat
bear
residu
substratemim
shown
residu
optim
interact
pocket
proteas
fig
fig
inhibitor
prevent
conform
chang
necessari
format
oxyanion
hole
studi
suggest
peptidomimet
suitabl
warhead
glulik
chemic
entiti
optim
interact
pocket
appropri
combin
hydrophob
residu
maxim
interact
pocket
factor
consid
enhanc
potenc
inhibitor
recent
base
observ
proteasebound
peptidyl
inhibitor
typic
adopt
conform
posit
weerwarna
et
al
design
synthes
novel
set
triazolebas
macrocycl
inhibitor
two
posit
link
use
suitabl
linker
preorgan
conform
optim
interact
noroviru
proteas
demonstr
structur
studi
addit
potenti
higher
stabil
metabol
enzym
inhibitor
exhibit
increas
cellular
permeabl
studi
anticip
direct
optim
design
strategi
improv
pharmacokinet
properti
metabol
stabil
hunov
proteas
inhibitor
use
structur
analysi
cellbas
assay
consid
activesit
residu
highli
conserv
hunov
proteas
variou
genogroup
picornaviru
proteas
distinct
possibl
design
broadspectrum
proteas
inhibitor
antivir
nov
rdrp
similar
picornaviru
critic
synthes
negativesens
rna
well
newli
made
positivesens
genom
rna
target
develop
small
molecul
inhibitor
xray
structur
rdrp
sever
nov
genogroup
includ
hunov
gii
sapoviru
murin
nov
determin
observ
rnadna
polymeras
protein
exhbit
typic
right
hand
configur
palm
finger
thumb
domain
fig
activ
site
locat
thumb
domain
consist
three
conserv
asp
residu
critic
mediat
catalysi
two
metalion
mechan
key
residu
arg
asn
ser
requir
substrat
bind
catalysi
crystallograph
studi
shown
nov
rdrp
exist
two
princip
conform
open
activ
site
conform
repres
inact
state
rdrp
close
activ
site
conform
prime
catalyz
nucleotidyl
transfer
reaction
optim
posit
nucleotid
rna
metal
ion
catalyt
reaction
signific
progress
identifi
small
molecul
inhibitor
nov
rdrp
use
silico
screen
understand
structur
basi
inhibit
analyz
cocryst
structur
rdrp
inhibitor
nonnucleosid
inhibitor
suramin
drug
use
treatment
sleep
sick
caus
protozoan
trypanosoma
analogu
consist
naphthalenetrisulfon
acid
moieti
shown
effect
inhibit
nov
rdrp
ic
low
nanomolar
rang
inhibitor
bind
rdrp
along
nucleotid
access
pathway
finger
thumb
domain
fig
nucleosideanalog
ribavirin
hepat
c
viru
polymeras
inhibitor
favipiravir
nucleosid
precursor
origin
develop
influenza
virus
shown
effect
inhibit
vitro
replic
murin
noroviru
mnv
also
hunov
replic
use
norwalk
viru
replicon
model
recent
studi
shown
triphosph
also
inhibit
mnv
hunov
rdrp
activ
ic
low
micromolar
rang
studi
found
triphosph
inhibit
rdrp
directli
compet
ctp
primer
elong
wherea
triphosph
compet
mostli
atp
gtp
initi
elong
step
structurebas
techniqu
coupl
high
throughput
screen
like
lead
design
develop
potent
perhap
even
broadspectrum
rdrp
inhibitor
necessari
pharmacokinet
properti
interferon
group
peptid
antivir
activ
varieti
virus
vitro
studi
demonstr
type
interferon
inhibit
noroviru
replic
replicon
system
although
human
studi
report
date
mnv
replic
inhibit
type
ii
interferon
recent
studi
also
demonstr
chronic
infect
caus
mnv
clear
administr
type
iii
interferon
interferon
absenc
adapt
immun
respons
addit
number
cellular
factor
la
ptb
hnrnp
identifi
critic
mnv
replic
use
rnai
methodolog
suggest
molecul
may
target
antivir
drug
develop
small
molecul
inhibitor
deubiquitinas
inhibit
mnv
replic
addit
sever
rna
virus
whether
approach
viabl
hunov
replic
need
studi
hunov
pose
signific
global
health
concern
current
lack
effect
antivir
strategi
intens
focu
vaccin
develop
well
antivir
drug
discoveri
recent
progress
front
encourag
immunogen
vlpbase
candid
vaccin
phaseii
clinic
trial
candid
vaccin
base
p
domain
elicit
strong
immun
respons
also
hold
promis
studi
rais
possibl
design
multival
vaccin
counter
antigen
genet
divers
exhibit
hunov
recent
progress
isol
character
hbgablock
human
mab
point
distinct
possibl
design
antibodybas
scaffold
immunotherapeut
agent
parallel
sever
studi
focus
select
nonstructur
protein
proteas
rdrp
small
molecul
drug
discoveri
studi
requir
optim
metabol
stabil
pharmacokinet
properti
progress
made
recent
year
produc
human
nov
cultur
cell
may
prove
critic
robust
optim
antivir
drug
lead
better
understand
mechan
underli
viru
replic
turn
may
pave
way
discov
novel
antivir
agent
combin
use
antivir
effect
vaccin
may
inde
realiz
near
futur
counter
control
hunov
infect
structur
norwalk
viru
proteas
bound
natur
substrat
pdb
id
pdb
id
proteas
depict
surfac
grey
cartoon
model
light
blue
substrat
bind
pocket
label
residu
form
catalyt
triad
shown
stick
model
red
label
activ
site
substrat
compris
residu
inf
shown
pink
stick
model
oxygen
nitrogen
atom
label
red
blue
respect
b
structur
norwalk
proteas
bound
substratebas
peptid
inhibitor
pdb
id
proteas
depict
similar
fig
inhibitor
repres
ball
stick
model
cyan
shown
mimic
substrat
bind
c
structur
noroviru
polymeras
rdrp
pdb
id
bound
primertempl
rna
duplex
rdrp
depict
surfac
cartoon
model
thumb
blue
finger
cyan
palm
pink
domain
along
n
light
yellow
ctermin
green
region
indic
activ
site
label
shown
bound
primertempl
rna
duplex
orang
structur
noroviru
polymeras
rdrp
pdb
id
bound
suramin
inhibitor
block
rna
exit
pathway
rdrp
structur
element
shown
use
color
code
fig
